Previous Close | 14.33 |
Open | 14.33 |
Bid | 9.51 x 3000 |
Ask | 15.77 x 1100 |
Day's Range | 14.33 - 14.33 |
52 Week Range | 10.25 - 20.50 |
Volume | 120 |
Avg. Volume | 404 |
Market Cap | 25.229M |
Beta (5Y Monthly) | 0.03 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.36 |
Earnings Date | Jan 08, 2021 - Jan 12, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Longevity Acquisition Corp. ("LOAC" or the "Company") (LOAC) relating to its proposed merger with 4D Pharma PLC. Under the terms of the agreement, LOAC shareholders will receive 7.5315 shares of 4D Pharma per share.
Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that on February 8, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Live Biotherapeutic products ("LBPs") - a novel class of drug derived from the microbiome, and a business combination target of LOAC, has announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. for BAVENCIO® (avelumab), the first and only immunotherapy approved as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma. BAVENCIO is co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer Inc.
Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that on February 3, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Live Biotherapeutic products ("LBPs") - a novel class of drug derived from the microbiome, and a business combination target of LOAC, has announced progress on activities in its development program for lead immuno-oncology single strain Live Biotherapeutic candidate MRx0518.